In-Vivo Electrophysiology Imaging

体内电生理学成像

基本信息

批准号：
7918053
负责人：
Barry London
金额：
$ 75.75万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-30 至 2013-07-31
项目状态：
已结题

项目摘要

Abstract Arrhythmias are a major cause of morbidity and mortality, with more than 250,000 people dying suddenly each year in the United States. Most arrhythmias are acquired and result from damage to the heart or its electrical system by ischemia, infarction, cardiac surgery, viruses, and assorted non- cardiac diseases. Our ability to identify which patients are at the highest risk of sudden death is poor, with ejection fraction being the only major clinical tool available for risk stratification. In addition, internal cardioverter-defibrillator (ICD) placement is the only effective therapy for high risk patients. Thus, the identification for novel tools to study arrhythmias in-vivo and stratify arrhythmic risk would represent a major advance to cardiovascular care. With the funding from the Pioneer Award, we will develop two novel and revolutionary techniques to image electrical activity in the intact heart in-vivo. First, we will adapt the most common clinical imaging technique, two-dimensional doppler echocardiography, to detect electrical activity in real time. Second, we will develop a modified autologous stem cell implant to detect adrenergic activity in the heart. These techniques will be developed in-vitro, tested in-vivo using animal models, and applied to humans when possible. If successful, both techniques will increase our understanding of arrhythmia mechanisms, improve risk stratification in patients at risk for sudden death, and guide therapeutic interventions.

抽象的心律失常是发病和死亡的主要原因，有超过 250,000 人死亡在美国每年都会突然发生这样的事。大多数心律失常是获得性的，是由心律损伤引起的心脏或其电气系统因缺血、梗塞、心脏手术、病毒和各种非心脏病。我们识别哪些患者猝死风险最高的能力很差，射血分数是唯一可用于风险分层的主要临床工具。此外，体内心脏复律除颤器 (ICD) 放置是对高危患者唯一有效的治疗方法。因此，确定用于研究体内心律失常和分层心律失常风险的新工具将代表了心血管护理的重大进步。在先锋奖的资助下，我们将开发两项新颖且革命性的技术对完整心脏的体内电活动进行成像。首先，我们将采用最常见的临床成像技术，二维多普勒超声心动图，实时检测电活动。其次，我们将开发一种改良的自体干细胞植入物来检测肾上腺素能活性心。这些技术将在体外开发，使用动物模型进行体内测试，并应用于如果可能的话，人类。如果成功，这两种技术将增加我们对心律失常的理解机制，改善猝死风险患者的风险分层，并指导治疗干预措施。